Open AccessDolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial
Author(s) -
Kelly E. Dooley,
Richard Kaplan,
Noluthando Mwelase,
Beatriz Grinsztejn,
Eduardo Ticona,
Marcus Lacerda,
Omar Sued,
Elena Belonosova,
Mounir AitKhaled,
Konstantinos Angelis,
Dannae Brown,
Rajendra Singh,
Christine L. Talarico,
Allan R. Tenorio,
Michael R Keegan,
Michael Aboud
Publication year - 2019
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciz256
Subject(s) - medicine , dolutegravir , efavirenz , tuberculosis , rifampicin , immune reconstitution inflammatory syndrome , population , clinical endpoint , randomized controlled trial , confidence interval , discontinuation , viral load , gastroenterology , immunology , human immunodeficiency virus (hiv) , antiretroviral therapy , pathology , environmental health
The concurrent treatment of tuberculosis and human immunodeficiency virus (HIV) is challenging, owing to drug interactions, overlapping toxicities, and immune reconstitution inflammatory syndrome (IRIS). The efficacy and safety of dolutegravir (DTG) were assessed in adults with HIV and drug-susceptible tuberculosis.